Literature DB >> 31770495

Prevalence, Characteristics, and Prognosis of Early Chronic Obstructive Pulmonary Disease. The Copenhagen General Population Study.

Yunus Çolak1,2,3, Shoaib Afzal1,2,3, Børge G Nordestgaard1,2,3, Jørgen Vestbo4, Peter Lange2,5,3,6.   

Abstract

Rationale: Identification of younger adults at high risk of developing chronic obstructive pulmonary disease (COPD) could lead to implementation of preventive measures before disease onset and halt progression.
Objectives: To investigate the prevalence, characteristics, and prognosis of individuals with early COPD in the general population.
Methods: We investigated 105,630 randomly chosen adults from a Danish contemporary population-based cohort. Early COPD was defined as FEV1/FVC less than the lower limit of normal in individuals under 50 years of age with 10 pack-years or greater of tobacco consumption.Measurements and Main
Results: Among 8,064 individuals under 50 years of age with 10 pack-years or greater of tobacco consumption, 1,175 (15%) had early COPD, of whom 58% were current smokers. Individuals with early COPD more often had chronic respiratory symptoms, severe lung function impairment, asthma, and a history with bronchitis/pneumonia. During the 14.4-year follow-up, we observed 117 acute hospitalizations with obstructive lung disease, 227 acute hospitalizations with pneumonia, and 185 deaths among the 8,064 younger adults. Compared with individuals without COPD, those with early COPD had multivariable adjusted hazard ratios of 6.42 (95% confidence interval, 3.39-12.2) for acute obstructive lung disease hospitalizations, 2.03 (1.43-2.88) for acute pneumonia hospitalizations, and 1.79 (1.28-2.52) for all-cause mortality.Conclusions: Among individuals under 50 years of age and 10 pack-years or greater of tobacco consumption from the general population, 15% fulfill criteria of early COPD. Individuals with early COPD more often have chronic respiratory symptoms and severe lung function impairment, and an increased risk of acute respiratory hospitalizations and early death.

Entities:  

Keywords:  FEV; airway obstruction; chronic bronchitis; diagnosis; emphysema

Mesh:

Year:  2020        PMID: 31770495      PMCID: PMC7068820          DOI: 10.1164/rccm.201908-1644OC

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN: 1073-449X            Impact factor:   21.405


  33 in total

1.  COPD in young patients: a pre-specified analysis of the four-year trial of tiotropium (UPLIFT).

Authors:  A H Morice; B Celli; S Kesten; T Lystig; D Tashkin; M Decramer
Journal:  Respir Med       Date:  2010-08-17       Impact factor: 3.415

Review 2.  Early-Life Origins of Chronic Obstructive Pulmonary Disease.

Authors:  Fernando D Martinez
Journal:  N Engl J Med       Date:  2016-09-01       Impact factor: 91.245

3.  Young and middle-aged adults with airflow limitation according to lower limit of normal but not fixed ratio have high morbidity and poor survival: a population-based prospective cohort study.

Authors:  Yunus Çolak; Shoaib Afzal; Børge G Nordestgaard; Jørgen Vestbo; Peter Lange
Journal:  Eur Respir J       Date:  2018-03-29       Impact factor: 16.671

4.  Recommendations for epidemiological studies on COPD.

Authors:  P S Bakke; E Rönmark; T Eagan; F Pistelli; I Annesi-Maesano; M Maly; M Meren; P Vermeire Dagger; J Vestbo; G Viegi; J Zielinski; B Lundbäck
Journal:  Eur Respir J       Date:  2011-12       Impact factor: 16.671

5.  Outcomes of Childhood Asthma and Wheezy Bronchitis. A 50-Year Cohort Study.

Authors:  Nara Tagiyeva; Graham Devereux; Shona Fielding; Stephen Turner; Graham Douglas
Journal:  Am J Respir Crit Care Med       Date:  2016-01-01       Impact factor: 21.405

6.  Chronic bronchitis before age 50 years predicts incident airflow limitation and mortality risk.

Authors:  S Guerra; D L Sherrill; C Venker; C M Ceccato; M Halonen; F D Martinez
Journal:  Thorax       Date:  2009-07-05       Impact factor: 9.139

7.  Association of chronic mucus hypersecretion with FEV1 decline and chronic obstructive pulmonary disease morbidity. Copenhagen City Heart Study Group.

Authors:  J Vestbo; E Prescott; P Lange
Journal:  Am J Respir Crit Care Med       Date:  1996-05       Impact factor: 21.405

Review 8.  What is early COPD and why is it important?

Authors:  Joan B Soriano; Francesca Polverino; Borja G Cosio
Journal:  Eur Respir J       Date:  2018-12-06       Impact factor: 16.671

9.  The Presence of Chronic Mucus Hypersecretion across Adult Life in Relation to Chronic Obstructive Pulmonary Disease Development.

Authors:  James P Allinson; Rebecca Hardy; Gavin C Donaldson; Seif O Shaheen; Diana Kuh; Jadwiga A Wedzicha
Journal:  Am J Respir Crit Care Med       Date:  2016-03-15       Impact factor: 21.405

Review 10.  COPD exacerbations: defining their cause and prevention.

Authors:  Jadwiga A Wedzicha; Terence A R Seemungal
Journal:  Lancet       Date:  2007-09-01       Impact factor: 79.321

View more
  23 in total

1.  Does Nutritional Risk Screening 2002 Correlate with the Dyspnea Status of Patients with GOLD Stage C-D Chronic Obstructive Pulmonary Disease?

Authors:  Nalan Ogan; Fatma Yıldırım; Banu Süzen; Ayşe Baha; Evrim Eylem Akpınar
Journal:  Turk Thorac J       Date:  2020-01-01

Review 2.  Treatment Trials in Young Patients with Chronic Obstructive Pulmonary Disease and Pre-Chronic Obstructive Pulmonary Disease Patients: Time to Move Forward.

Authors:  Fernando J Martinez; Alvar Agusti; Bartolome R Celli; MeiLan K Han; James P Allinson; Surya P Bhatt; Peter Calverley; Sanjay H Chotirmall; Badrul Chowdhury; Patrick Darken; Carla A Da Silva; Gavin Donaldson; Paul Dorinsky; Mark Dransfield; Rosa Faner; David M Halpin; Paul Jones; Jerry A Krishnan; Nicholas Locantore; Fernando D Martinez; Hana Mullerova; David Price; Klaus F Rabe; Colin Reisner; Dave Singh; Jørgen Vestbo; Claus F Vogelmeier; Robert A Wise; Ruth Tal-Singer; Jadwiga A Wedzicha
Journal:  Am J Respir Crit Care Med       Date:  2022-02-01       Impact factor: 21.405

3.  Prevalence and Population Attributable Risk for Early Chronic Obstructive Pulmonary Disease in U.S. Hispanic/Latino Individuals.

Authors:  Fariha Khalid; Wei Wang; David Mannino; Alejandro A Diaz
Journal:  Ann Am Thorac Soc       Date:  2022-03

4.  Update in Chronic Obstructive Pulmonary Disease 2020.

Authors:  Andy I Ritchie; Jonathon R Baker; Trisha M Parekh; James P Allinson; Surya P Bhatt; Louise E Donnelly; Gavin C Donaldson
Journal:  Am J Respir Crit Care Med       Date:  2021-07-01       Impact factor: 21.405

Review 5.  Advances in Chronic Obstructive Pulmonary Disease.

Authors:  Michael C Ferrera; Wassim W Labaki; MeiLan K Han
Journal:  Annu Rev Med       Date:  2021-01-27       Impact factor: 13.739

Review 6.  Impaired Respiratory Health and Life Course Transitions From Health to Chronic Lung Disease.

Authors:  Gabrielle Y Liu; Ravi Kalhan
Journal:  Chest       Date:  2021-04-15       Impact factor: 10.262

7.  Supernormal lung function and risk of COPD: A contemporary population-based cohort study.

Authors:  Yunus Çolak; Børge G Nordestgaard; Peter Lange; Jørgen Vestbo; Shoaib Afzal
Journal:  EClinicalMedicine       Date:  2021-06-18

8.  The Complex Beginnings of Chronic Obstructive Pulmonary Disease.

Authors:  Stefano Guerra; Fernando D Martinez
Journal:  Am J Respir Crit Care Med       Date:  2020-03-15       Impact factor: 21.405

9.  Phenotypic characterisation of early COPD: a prospective case-control study.

Authors:  Borja G Cosío; Sergi Pascual-Guardia; Alicia Borras-Santos; Germán Peces-Barba; Salud Santos; Laura Vigil; Juan José Soler-Cataluña; Cristina Martínez-González; Ciro Casanova; Pedro J Marcos; Carlos J Alvarez; José Luis López-Campos; Joaquim Gea; Judith Garcia-Aymerich; Jesús Molina; Miguel Román; Jorge Moises; Viktoria Szabo; Elizabeth A Reagan; Raúl San José Estépar; George Washko; Alvar Agustí; Rosa Faner
Journal:  ERJ Open Res       Date:  2020-10-05

Review 10.  The Importance of Appropriate Diagnosis in the Practical Management of Chronic Obstructive Pulmonary Disease.

Authors:  Naozumi Hashimoto; Keiko Wakahara; Koji Sakamoto
Journal:  Diagnostics (Basel)       Date:  2021-03-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.